Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
125.4 USD | -0.92% | -0.76% | +15.07% |
Feb. 09 | Adagene Gets China Clearance to Assess Colorectal Cancer Treatment Combination | MT |
Feb. 08 | US Senate Democrats grill pharma CEOs on drug prices | RE |
Financials (USD)
Sales 2023 | 60.12B | Sales 2024 * | 63.48B | Capitalization | 318B |
---|---|---|---|---|---|
Net income 2023 | 365M | Net income 2024 * | 19.55B | EV / Sales 2023 | 4.6 x |
Net Debt 2023 * | 28.54B | Net Debt 2024 * | 18.76B | EV / Sales 2024 * | 5.3 x |
P/E ratio 2023 |
779
x | P/E ratio 2024 * |
16.1
x | Employees | 68,000 |
Yield 2023 * |
2.32% | Yield 2024 * |
2.59% | Free-Float | 70.8% |
Latest transcript on Merck & Co., Inc.
1 day | -0.92% | ||
1 week | -0.76% | ||
Current month | +3.87% | ||
1 month | +5.54% | ||
3 months | +23.73% | ||
6 months | +18.83% | ||
Current year | +15.07% |
Managers | Title | Age | Since |
---|---|---|---|
Robert Davis
CEO | Chief Executive Officer | 57 | 14-03-31 |
Director of Finance/CFO | 55 | 89-12-31 | |
Compliance Officer | 42 | 18-01-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Tom Glocer
BRD | Director/Board Member | 63 | 07-11-26 |
Pamela Craig
BRD | Director/Board Member | 66 | 15-08-31 |
Inge Thulin
BRD | Director/Board Member | 69 | 18-02-28 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
14.34% | 232 M€ | +7.20% | - | |
5.61% | 19 M€ | +2.97% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-02-09 | 125.4 | -0.92% | 7,891,392 |
24-02-08 | 126.6 | -0.67% | 6,308,268 |
24-02-07 | 127.5 | +0.47% | 6,742,760 |
24-02-06 | 126.9 | +0.55% | 6,152,994 |
24-02-05 | 126.2 | -0.18% | 8,027,717 |
Delayed Quote Nyse, February 09, 2024 at 04:00 pm EST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+15.07% | 318 B $ | |
+26.97% | 666 B $ | |
+19.17% | 536 B $ | |
+0.01% | 377 B $ | |
+12.33% | 307 B $ | |
-8.02% | 207 B $ | |
+4.05% | 206 B $ | |
-7.92% | 191 B $ | |
-4.27% | 156 B $ | |
-3.63% | 117 B $ |